SCHEMBL7556522

SCHEMBL7556522

C=CC(C)NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.46
KIF11 P52732 1/20 0.35
HSP90AA1 P07900 1/20 0.35
CYP2D6 P10635 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALDH1A1 P00352 4/20 0.32
TSHR P16473 4/20 0.32
CACNA1F O60840 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
ADRA2B P18089 1/20 0.32
CHRM3 P20309 1/20 0.32
ADRA1A P35348 1/20 0.32
HRH1 P35367 1/20 0.32
OPRK1 P41145 1/20 0.32
CACNA1D Q01668 1/20 0.32
SLC6A3 Q01959 1/20 0.32
KCNH2 Q12809 1/20 0.32
CACNA1S Q13698 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10675289 0.74 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2ALDH1A1
SCHEMBL4495324 0.74 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2CYP3A4
SCHEMBL9025613 0.74 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2ALDH1A1
SCHEMBL16673174 0.74 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2ALDH1A1
SCHEMBL2160833 0.74 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2SLC6A3
SCHEMBL19381442 0.71 KCNN4 (0.46) KCNN4KIF11CYP2D6CYP1A2CYP3A4
SCHEMBL6566499 0.71 KCNN4 (0.52) KCNN4KIF11HSP90AA1CYP3A4ALDH1A1
SCHEMBL16609226 0.71 KCNN4 (0.52) KCNN4KIF11HSP90AA1CYP3A4ALDH1A1
SCHEMBL2350755 0.70 TDP1 (0.56) CYP3A4ALDH1A1TSHRMAPK1TDP1
SCHEMBL2552806 0.69 KCNN4 (0.45) KCNN4KIF11CYP2D6CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252162-B1 ALPHA V INTEGRIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-07-25 EP disclosed
US-6472403-B2 IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH MERCK & CO., INC. 2002-10-29 US disclosed
US-20020037889-A1 Alpha V integrin receptor antagonists MERCK SHARP & DOHME CORP. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037889-A1 Alpha V integrin receptor antagonists ITGAV, ITGB3, ITGA5 KCNN4 4186/4885KIF11 4696/4885HSP90AA1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.